tacrine hydrochloride
Recently Published Documents


TOTAL DOCUMENTS

28
(FIVE YEARS 3)

H-INDEX

10
(FIVE YEARS 1)

2020 ◽  
Vol 217 (8) ◽  
Author(s):  
Qingxin Zhou ◽  
Meihua Lin ◽  
Xing Feng ◽  
Fei Ma ◽  
Yuekun Zhu ◽  
...  

CDC-like kinase 3 (CLK3) is a dual specificity kinase that functions on substrates containing serine/threonine and tyrosine. But its role in human cancer remains unknown. Herein, we demonstrated that CLK3 was significantly up-regulated in cholangiocarcinoma (CCA) and identified a recurrent Q607R somatic substitution that represented a gain-of-function mutation in the CLK3 kinase domain. Gene ontology term enrichment suggested that high CLK3 expression in CCA patients mainly was associated with nucleotide metabolism reprogramming, which was further confirmed by comparing metabolic profiling of CCA cells. CLK3 directly phosphorylated USP13 at Y708, which promoted its binding to c-Myc, thereby preventing Fbxl14-mediated c-Myc ubiquitination and activating the transcription of purine metabolic genes. Notably, the CCA-associated CLK3-Q607R mutant induced USP13-Y708 phosphorylation and enhanced the activity of c-Myc. In turn, c-Myc transcriptionally up-regulated CLK3. Finally, we identified tacrine hydrochloride as a potential drug to inhibit aberrant CLK3-induced CCA. These findings demonstrate that CLK3 plays a crucial role in CCA purine metabolism, suggesting a potential therapeutic utility.


2019 ◽  
Vol 16 (10) ◽  
pp. 902-912 ◽  
Author(s):  
Sonal Setya ◽  
Tushar Madaan ◽  
Bal Kishen Razdan ◽  
Mamta Farswan ◽  
Sushama Talegaonkar

Background: Alzheimer’s disease is a chronic progressive neurodegenerative disorder associated with depletion of acetylcholine. Oral treatment with tacrine hydrochloride; a reversible inhibitor of acetylcholinesterase, finds limited use in Alzheimer’s disease due to frequent dosing, hepatotoxicity and extensive pre-systemic metabolism. Objectives: The objective of the study was to evaluate pharmacokinetic, pharmacodynamic, safety and stability profile of transdermal w/o nanoemulsion gel of tacrine hydrochloride and determine its relative bioavailability from transdermal nanogel in contrast to marketed capsule and conventional hydrogel. Methods: The optimized nanoemulsion gel NEGT4 (droplet size 156.4 ±0.48 nm, with poly dispersity index 0.36 ±0.4, permeation flux 6.172±2.94 µg/cm2/h across rat skin) was prepared by spontaneous emulsification followed by sonication. NEGT4 contained 7 mg of drug in 10% w/w distilled water, 30% w/w surfactant (Labrafil M) and cosurfactant (Transcutol P) mixture in ratio 1:4 and 60 % Capryol 90 as oily phase thickened with 98.9 mg ethyl cellulose (20 cps). In vivo studies were carried out on male Wistar rats following standard guidelines. Scopolamine was used to induce amnesia in rats which is a characteristic of Alzheimer’s disease. Various formulations were compared by performing pharmacokinetic, histopathological, behavioural and biochemical studies on rats. Stability studies on nanoemulsion gels were carried out in accordance with The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines. Results: Pharmacokinetic studies exhibited significantly greater extent of absorption from NEGT4 in comparison to capsule and hydrogel with a 2.18 and 5.26-fold increase respectively. Significant improvement in neurobehavioral parameters was observed with NEGT4 in scopolamine-induced amnesic rats. Biochemical assessment showed superior anti-amnesic activity of NEGT4 through augmentation of antioxidant enzymes, decreased lipid peroxidation and acetylcholinesterase activity. Low value of serum aminotransferase in rats treated with NEGT4 indicated the absence of hepatotoxicity. NEGT4 was found to be non-irritant and possessed a shelf life of 4.11 years. Conclusion: Developed nanoemulsion gel of tacrine hydrochloride was found to be safe, stable, and efficacious and has immense potential to be used in the therapy of Alzheimer’s disease.


Author(s):  
Jeroen Jacobs ◽  
Michele Moris ◽  
Tim De Samber ◽  
Johannes Vrijdag ◽  
Wim De Borggraeve ◽  
...  

Crystallization of tacrine hydrochloride, an acetylcholinesterase inhibitor used during treatment of mild to moderate Alzheimer's disease, from a water:ethanol solution has resulted in an orthorhombic pseudopolymorph. This orthorhombic form which occurs as a dihydrate shows columns of stacking acridines together with continuous Cl—Owater—Owater—Cl chains and ladder-like ribbons composed of squares and hexagons.


2014 ◽  
Vol 24 (4) ◽  
pp. 323-335 ◽  
Author(s):  
Giuseppe Corace ◽  
Cristina Angeloni ◽  
Marco Malaguti ◽  
Silvana Hrelia ◽  
Paul C. Stein ◽  
...  

2012 ◽  
Vol 3 (1) ◽  
pp. 33-41 ◽  
Author(s):  
Bruno Saladini ◽  
Federica Bigucci ◽  
Teresa Cerchiara ◽  
Maria Caterina Gallucci ◽  
Barbara Luppi

Sign in / Sign up

Export Citation Format

Share Document